Tachyphylaxis vs tolerance — pharmacological distinction on GLP-1

VanRx_Mike said:

Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest…

Bookmarking. The distinction being drawn above is the one nobody else makes.

Clinical perspective, offered as context rather than as advice. Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the correction. That is slower than asserting, and it is the only version that survives being wrong.

That is the short version; the long version is somebody else's post.

Dr.AddMedPHL said:

I want to add the drug interaction perspective on the pharmacology.

Pushing back on Dr.AddMedPHL here. I think the framing smuggles in the conclusion. Ask it the other way round and the obvious answer reverses, which usually means the question is doing the work.

Adding the numbers, since they settle part of this. Keep the original post as written when you update it, and add the correction underneath. An edited-away mistake is invisible to the next person who makes it.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here.